Showing 2791-2800 of 3315 results for "".
- Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trialshttps://modernod.com/news/dopavision-closes-e12-million-series-a-round-to-advance-digital-childhood-myopia-therapeutic-through-clinical-trials/2479372/Dopavision announced the closing of a €12 million Series A financing round. The proceeds will be used to fund the clinical development of MyopiaX, the company’s lead product in childhood myopia, with the goal to demonstrate its safety and efficacy in clinical studies and advance this innova
- Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical Advisory Boardhttps://modernod.com/news/aurion-biotech-appoints-professor-shigeru-kinoshita-md-phd-to-its-medical-advisory-board/2479369/Shigeru Kinoshita, MD, PhD, has joined the medical advisory board at Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases. Professor Kinoshita is the inventor of Aurion Biotech’s lead candidate, cell therapy for
- EyePoint Pharmaceuticals Reports Positive 30-Day Safety Results for All Cohorts From DAVIO Trial of EYP-1901 for Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-reports-positive-30-day-safety-results-for-all-cohorts-from-the-davio-trial-of-eyp-1901-for-wet-amd/2479344/EyePoint Pharmaceuticals announced positive safety results from its phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (AMD). All dose cohorts have reached at least 30-day post-dosing foll
- PYC Therapeutics Announces Preclinical Results Demonstrating VP-002 Program’s Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophyhttps://modernod.com/news/pyc-therapeutics-announces-comprehensive-preclinical-results-demonstrating-vp-002-programs-potential-as-the-first-disease-modifying-therapy-for-autosomal-dominant-optic-atrophy/2479330/PYC Therapeutics released a summary of preclinical findings supporting the potential of PYC’s VP-002 program as the first disease-modifying therapy for patients suffering from Autosomal Dominant Optic Atrophy (ADOA). PYC’s PPMO technology used in the VP-002 program significantly increases levels
- Recycling of the Eye’s Light Sensors Is Faulty in Progressive Blindness of Older Adults, University of Maryland School of Medicine Researchers Showhttps://modernod.com/news/recycling-of-the-eyes-light-sensors-is-faulty-in-progressive-blindness-of-older-adults-university-of-maryland-school-of-medicine-researchers-show/2479329/With the National Eye Institute reporting that about 11 million older adults in the U.S. endure a condition that leads to progressive blindness, known as age-related macular degeneration, University of Maryland School of Medicine (UMSOM) researchers are starting to understand what goes wrong in t
- Allergan Adds Two Experts to Eye Care Divisionhttps://modernod.com/news/allergan-adds-two-experts-to-eye-care-division/2479311/Allergan has announced two new additions to leadership roles in Allergan Eye Care. E. Randy Craven, MD, FACS, has joined Allergan Eye Care as medical director of the U.S. medical affairs glaucoma organization. A pioneer of minimally-invasive glaucoma surgery, Dr. Craven previously served a
- Alcon’s ORA System Reaches 2 Million Caseshttps://modernod.com/news/alcons-ora-system-reaches-2-million-cases/2479303/Alcon announced its Optiwave Refractive Analysis (ORA) intraoperative aberrometer system has reached 2 million cases worldwide. This milestone signifies an important leap forward in cataract surgery by delivering greater accuracy than preoperative calculation methods alone. The ORA Syste
- Biogen Fails to Meet Primary or Secondary Endpoints in Phase 3 Gene Therapy Study in Choroideremiahttps://modernod.com/news/biogen-fails-to-meet-primary-or-secondary-endpoints-in-phase-3-gene-therapy-study-in-choroideremia/2479291/Biogen announced topline results from the phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia. The STAR study did not meet its primary endpoint of proportion of participants with a ≥15 letter improvement fr
- Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotechhttps://modernod.com/news/arnaud-lacoste-is-named-chief-scientific-officer-of-aurion-biotech/2479293/Arnaud Lacoste, MBA, PhD, has been named chief scientific officer of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies. Arnaud will lead R&D teams based in Boston and Seattle. “Arnaud is a brilliant scientist, a strategic e
- EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Studyhttps://modernod.com/news/eyegate-pharma-announces-first-patient-dosed-for-pp-001-in-a-phase-2-proof-of-concept-ocular-surface-inflammation-study/2479289/EyeGate Pharmaceuticals announced the first patient dosed in phase 2 proof-of-concept study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001, an immune-modulating molecule, is an in